Drug Discount Programs Create More Cloud In Quest For Transparency
Executive Summary
Behind a popular drug discount program are pharmacy benefits managers and even drug companies themselves, raising questions about whether such businesses may yet be another player in an opaque and complicated supply chain that is facilitating higher US drug prices, even as the most prominent company in the space, GoodRx, routinely criticizes soaring list prices.
You may also be interested in...
Diabetes, Blood-Thinners Dominate Copay Support, But Assistance May Not Be Well Targeted To Need
New comprehensive study of drug coupons offered by manufacturers, pharmacies, pharmacy benefit managers and state programs, and who uses the discounts, takes a more holistic look at patient assistance programs than previous work. Researchers raise concerns that the offsets don’t seem well targeted at people with high financial or clinical need.
US FDA Mum On Whether Woodcock Would Stick Around Long-Term For Califf
Woodcock’s willingness to stay on at US FDA for more than a transitional period after Robert Califf’s expected confirmation as commissioner may depend on exactly the type of authority and tasks he’d be willing to delegate to her. Plus, some other agency personnel updates.
Pink Sheet Podcast: Woodcock’s Legacy, Merck’s Oral COVID-19 Pill, 340B Case At Supreme Court
Pink Sheet reporters and editor review US FDA Acting Commissioner Janet Woodcock’s long career and update Robert Califf’s confirmation process, consider the advisory committee for Merck’s COVID-19 pill, and discuss an under-the-radar case on 340B policy at the US Supreme Court.